RT Journal Article
SR Electronic
T1 Polygenic basis and biomedical consequences of telomere length variation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21253516
DO 10.1101/2021.03.23.21253516
A1 Codd, Veryan
A1 Wang, Qingning
A1 Allara, Elias
A1 Musicha, Crispin
A1 Kaptoge, Stephen
A1 Stoma, Svetlana
A1 Jiang, Tao
A1 Hamby, Stephen E.
A1 Braund, Peter S.
A1 Bountziouka, Vasiliki
A1 Budgeon, Charley A.
A1 Denniff, Matthew
A1 Swinfield, Chloe
A1 Papakonstantinou, Manolo
A1 Sheth, Shilpi
A1 Nanus, Dominika E.
A1 Warner, Sophie C.
A1 Wang, Minxian
A1 Khera, Amit V.
A1 Eales, James
A1 Ouwehand, Willem H.
A1 Thompson, John R
A1 Angelantonio, Emanuele Di
A1 Wood, Angela M.
A1 Butterworth, Adam S.
A1 Danesh, John N.
A1 Nelson, Christopher P.
A1 Samani, Nilesh J.
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.23.21253516.abstract
AB Telomeres, the end fragments of chromosomes, play key roles in cellular proliferation and senescence1. Here we characterize the genetic architecture of naturally-occurring variation in leucocyte telomere length (LTL) and identify causal links between LTL and biomedical phenotypes in 472,174 well-characterized participants in UK Biobank2. We identified 197 independent sentinel variants associated with LTL at 138 genomic loci (108 novel). Genetically-determined differences in LTL were associated with multiple biological traits, ranging from height to bone marrow function, as well as several diseases spanning neoplastic, vascular, and inflammatory pathologies. Finally, we estimated that at age 40 years, people with >1-SD shorter compared to ≥1-SD longer LTL than the population mean had 2.5 years lower life expectancy. Overall, we furnish novel insights into the genetic regulation of LTL, reveal LTL’s wide-ranging influences on physiological traits, diseases, and longevity, and provide a powerful resource available to the global research community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been conducted using the UK Biobank Resource under Application Number 6077 and was funded by the UK Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council and British Heart Foundation (BHF) through MRC grant MR/M012816/1. C.P.N is funded by the BHF (SP/16/4/32697). V.C., C.A.B., C.M., V.B., Q.W., R.B., C.P.N. and N.J.S. are supported by the National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Centre (BRC-1215-20010). Cambridge University investigators are supported by the B.H.F (RG/13/13/30194; RG/18/13/33946), Health Data Research UK, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024) and MRC (MR/L003120/1). J.D. holds a BHF Personal Professorship and NIHR Senior Investigator Award. A.M.W. and E.A. received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart (11607).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank has ethical approval from the North West Centre for Research Ethics Committee (Application 11/NW/0382), which covers the UK. UK Biobank obtained informed consent from all participants. Full details can be found at https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. The work in this manuscript was approved by UK Biobank (Application 6077). The generation and use of the data presented in this paper was approved by the UK Biobank access committee under UK Biobank application number 6077.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data is accessible via application to UK Biobank. Summary statistics of the GWAS are available on request to the corresponding authors.